These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 19956633

  • 1. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.
    Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP.
    PLoS One; 2009 Nov 30; 4(11):e8025. PubMed ID: 19956633
    [Abstract] [Full Text] [Related]

  • 2. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.
    Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, Moffitt H, Sathasivam K, Bates GP.
    Brain Res Bull; 2007 Apr 30; 72(2-3):83-97. PubMed ID: 17352931
    [Abstract] [Full Text] [Related]

  • 3. Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice.
    Young D, Mayer F, Vidotto N, Schweizer T, Berth R, Abramowski D, Shimshek DR, van der Putten PH, Schmid P.
    PLoS One; 2013 Apr 30; 8(9):e75108. PubMed ID: 24086450
    [Abstract] [Full Text] [Related]

  • 4. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
    Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, Lopez E, Myers RH, MacDonald ME, Wheeler VC.
    Hum Mol Genet; 2006 Jun 15; 15(12):2015-24. PubMed ID: 16687439
    [Abstract] [Full Text] [Related]

  • 5. Transgenic models of Huntington's disease.
    Sathasivam K, Hobbs C, Mangiarini L, Mahal A, Turmaine M, Doherty P, Davies SW, Bates GP.
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun 29; 354(1386):963-9. PubMed ID: 10434294
    [Abstract] [Full Text] [Related]

  • 6. Formation of polyglutamine inclusions in non-CNS tissue.
    Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F, Wanker EE, Doherty P, Davies SW, Bates GP.
    Hum Mol Genet; 1999 May 29; 8(5):813-22. PubMed ID: 10196370
    [Abstract] [Full Text] [Related]

  • 7. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
    Franich NR, Hickey MA, Zhu C, Osborne GF, Ali N, Chu T, Bove NH, Lemesre V, Lerner RP, Zeitlin SO, Howland D, Neueder A, Landles C, Bates GP, Chesselet MF.
    J Neurosci Res; 2019 Dec 29; 97(12):1590-1605. PubMed ID: 31282030
    [Abstract] [Full Text] [Related]

  • 8. Light and electron microscopic characterization of the evolution of cellular pathology in the Hdh(CAG)150 Huntington's disease knock-in mouse.
    Bayram-Weston Z, Torres EM, Jones L, Dunnett SB, Brooks SP.
    Brain Res Bull; 2012 Jun 01; 88(2-3):189-98. PubMed ID: 21511013
    [Abstract] [Full Text] [Related]

  • 9. Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients.
    Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, Shima DT, Bates GP.
    Hum Mol Genet; 2001 Oct 01; 10(21):2425-35. PubMed ID: 11689489
    [Abstract] [Full Text] [Related]

  • 10. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.
    Rising AC, Xu J, Carlson A, Napoli VV, Denovan-Wright EM, Mandel RJ.
    Exp Neurol; 2011 Apr 01; 228(2):173-82. PubMed ID: 21192926
    [Abstract] [Full Text] [Related]

  • 11. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.
    Cowin RM, Roscic A, Bui N, Graham D, Paganetti P, Jankowsky JL, Weiss A, Paylor R.
    Behav Brain Res; 2012 Apr 15; 229(2):308-19. PubMed ID: 22306231
    [Abstract] [Full Text] [Related]

  • 12. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
    Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R.
    Hum Mol Genet; 2007 Aug 01; 16(15):1845-61. PubMed ID: 17519223
    [Abstract] [Full Text] [Related]

  • 13. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
    Morton AJ, Glynn D, Leavens W, Zheng Z, Faull RL, Skepper JN, Wight JM.
    Neurobiol Dis; 2009 Mar 01; 33(3):331-41. PubMed ID: 19130884
    [Abstract] [Full Text] [Related]

  • 14. Early Neurodegeneration in R6/2 Mice Carrying the Huntington's Disease Mutation with a Super-Expanded CAG Repeat, Despite Normal Lifespan.
    Kielar C, Morton AJ.
    J Huntingtons Dis; 2018 Mar 01; 7(1):61-76. PubMed ID: 29480204
    [Abstract] [Full Text] [Related]

  • 15. Light and electron microscopic characterization of the evolution of cellular pathology in HdhQ92 Huntington's disease knock-in mice.
    Bayram-Weston Z, Jones L, Dunnett SB, Brooks SP.
    Brain Res Bull; 2012 Jun 01; 88(2-3):171-81. PubMed ID: 21513775
    [Abstract] [Full Text] [Related]

  • 16. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH, Charles V, Williams M, Miller G, Whetsell WO, Tagle DA.
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun 29; 354(1386):1035-45. PubMed ID: 10434303
    [Abstract] [Full Text] [Related]

  • 17. Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death.
    Conforti P, Camnasio S, Mutti C, Valenza M, Thompson M, Fossale E, Zeitlin S, MacDonald ME, Zuccato C, Cattaneo E.
    Neurobiol Dis; 2013 Feb 29; 50():160-70. PubMed ID: 23089356
    [Abstract] [Full Text] [Related]

  • 18. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y, Igarashi S, Nakamura M, Gafni J, Torcassi C, Schilling G, Crippen D, Wood JD, Sawa A, Jenkins NA, Copeland NG, Borchelt DR, Ross CA, Ellerby LM.
    Neurobiol Dis; 2006 Feb 29; 21(2):381-91. PubMed ID: 16150600
    [Abstract] [Full Text] [Related]

  • 19. Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Wanderer J, Morton AJ.
    Histochem Cell Biol; 2007 May 29; 127(5):473-84. PubMed ID: 17285342
    [Abstract] [Full Text] [Related]

  • 20. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
    Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ.
    Mol Ther; 2005 Oct 29; 12(4):618-33. PubMed ID: 16019264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.